EUVIMEDEUVIMED entdecken
Crossref

Relapse risk factors and clinical characteristics of idiopathic inflammatory myopathies in 105 patients

Jihye Choi, So Hye Nam, Jung Sun Lee, Soo Min Ahn, Seokchan Hong, Yong-Gil Kim, Chang-Keun Lee, Jinseok Kim, Byeongzu Ghang, Bin Yoo

Clinical Rheumatology · 2024

DOI: 10.1007/s10067-024-07120-1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Rheumatology, 2024. Verfasst von Jihye Choi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Jeju National University College of Medicine, Jeju, Republic of Korea. Hauptthemen laut MEDLINE: Myositis, Recurrence, Glucocorticoids, Antibodies, Antinuclear. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: Jeju National University Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: To identify the risk factors for relapse of idiopathic inflammatory myopathies (IIMs). METHODS: Patients who were newly diagnosed with IIMs and underwent muscle biopsy between 2000 and 2017 at Asan Medical Center were retrospectively reviewed. The relapse of IIMs was defined as the recurrence of muscle or cutaneous manifestations with a ≥50% increase in glucocorticoid dosage after reaching the low-dose glucocorticoid phase with clinically significant improvement. The factors associated with the relapse of IIMs were investigated by Cox proportional hazards analysis. RESULTS: Of 105 patients with IIMs, relapse was observed in 65 patients (62%). The titer of antinuclear antibody (ANA) was higher in the relapse group than in the non-relapse group (P = 0.033). Multivariable analysis showed that the relapse of IIMs was significantly associated with histopathologic features consistent with IIMs (hazard ratio [HR], 1.69; 95% confidence interval [CI], 1.01-2.83, P = 0.045) and the use of immunosuppressants before relapse (HR, 0.50; 95% CI, 0.29-0.86, P = 0.013). Doubling of ANA titer was also associated with relapse, albeit without statistical significance (HR, 1.13; 95% CI, 1.00-1.27, P = 0.052). CONCLUSION: In patients with IIMs, the use of immunosuppressants had a significant negative association with relapse. Administering immunosuppressants from the early period during the initial glucocorticoid tapering phase may be useful in reducing the risk of relapse in patients with IIMs. Key Points • Since idiopathic inflammatory myopathies (IIMs) have a low prevalence, it is poorly understood which factors are associated with the relapse of IIMs. • In this study, about two-thirds of 105 patients with IIMs experienced a relapse of IIMs. • The risk of relapse in patients with IIMs was negatively associated with the use of immunosuppressants during glucocorticoid tapering and low-dose glucocorticoid phase. • Even in less severe cases, the use of immunosuppressants might be a good option for the management of IIMs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MyositisRecurrenceGlucocorticoidsAntibodies, AntinuclearImmunosuppressive AgentsHumansFemaleMaleMiddle AgedRisk FactorsRetrospective StudiesAdultProportional Hazards ModelsAgedMuscle, SkeletalBiopsy

Stichwörter der Autor:innen

DermatomyositisImmunosuppressive agentsPolymyositisRelapseRisk factors

Substanzen

GlucocorticoidsAntibodies, AntinuclearImmunosuppressive Agents

Autor:innen und Institutionen

  • Jeju National University College of Medicine, Jeju, Republic of Korea.
  • Division of Rheumatology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
  • Division of Rheumatology, Department of Internal Medicine, Seoul Veterans Hospital, Seoul, Republic of Korea.
  • Division of Rheumatology, Department of Internal Medicine, Jeju National University School of Medicine, Jeju National University Hospital, Jeju, Republic of Korea.
  • Division of Rheumatology, Department of Internal Medicine, Jeju National University School of Medicine, Jeju National University Hospital, Jeju, Republic of Korea. indream81@naver.com.
  • Division of Rheumatology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. byoo@amc.seoul.kr.

Förderung

  • Jeju National University Hospital

Zitieren

APA

Choi, J., Nam, S. H., Lee, J. S., Ahn, S. M., Hong, S., Kim, Y. G., Lee, C. K., Kim, J., Ghang, B., & Yoo, B. (2024). Relapse risk factors and clinical characteristics of idiopathic inflammatory myopathies in 105 patients. Clinical Rheumatology. https://doi.org/10.1007/s10067-024-07120-1

Vancouver

Choi J, Nam SH, Lee JS, Ahn SM, Hong S, Kim YG, et al. Relapse risk factors and clinical characteristics of idiopathic inflammatory myopathies in 105 patients. Clinical Rheumatology. 2024. doi:10.1007/s10067-024-07120-1

BibTeX
@article{Choi2024,
  author = {Choi, Jihye and Nam, So Hye and Lee, Jung Sun and Ahn, Soo Min and Hong, Seokchan and Kim, Yong-Gil and Lee, Chang-Keun and Kim, Jinseok and Ghang, Byeongzu and Yoo, Bin},
  title = {Relapse risk factors and clinical characteristics of idiopathic inflammatory myopathies in 105 patients},
  journal = {Clinical Rheumatology},
  year = {2024},
  doi = {10.1007/s10067-024-07120-1}
}
Kostenlos starten →